The hemp stock price reached $2.41 today, marking its highest point in 14 trading sessions. Market watchers attribute this surge to increased exports and potential partnerships with pharmaceutical distributors. Options data from Barchart points to heightened volatility for Tilray shares, with traders pricing in a 23.43% move through the end of this week. At its Mildura facility in Victoria , Cann Group produces its Satipharm CBD sleep capsules and multiple medical marijuana products, included cannabis flower and cannabis resin, to patients for a range of conditions from multiple sclerosis to chronic pain. The company has the annual capacity to produce 12,500 kilograms of dry cannabis flower for international and domestic medical cannabis markets. Market analysts tracking hemp stock price point to declining input costs for cultivation, improving gross margins. If margins expand further, valuation multiples could support a new price base above $2.